PRESTO

Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group

Die Studie eignet sich für: Adenokarzinom des Ösophagus im Frühstadium (einschl. Adenokarzinom des gastroösophagealen Übergangs)